OrthoPediatrics Corp (KIDS) FinancialsKIDSOrthoPediatrics Corp

OrthoPediatrics Corp (KIDS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Trauma and Deformity, accounting for 74.6% of total sales, equivalent to $52.63M. Other significant revenue streams include Scoliosis and Sports Medicine and Other. Understanding this composition is critical for investors evaluating how KIDS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, OrthoPediatrics Corp maintains a gross margin of 74.27%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.77%, while the net margin is -10.16%. These profitability ratios, combined with a Return on Equity (ROE) of -11.36%, provide a clear picture of how effectively KIDS converts its operational activities into shareholder value.

In the context of the broader market, KIDS competes directly with industry leaders such as AVR and PACB. With a market capitalization of $573.11M, it holds a significant position in the sector. When comparing efficiency, KIDS's gross margin of 74.27% stands against AVR's 76.91% and PACB's 30.26%. Such benchmarking helps identify whether OrthoPediatrics Corp is trading at a premium or discount relative to its financial performance.

The company has demonstrated strong revenue growth, with Q2 revenue of $70.51 million and a gross margin of 74%. Despite recent losses, the revenue guidance for 2026 has been raised to between $265 million and $269 million, indicating a projected growth rate of 12% to 14%.